(Reuters) – The U.S. Food and Drug Administration on Wednesday approved Bavarian Nordic’s plans to ramp up manufacturing of its Jynneos vaccine that is being used in efforts to stem a global outbreak of monkeypox.
After completing the inspection of a manufacturing plant earlier this month, the FDA has determined the vaccine made at the plant meets the agency’s quality standards, it said in a tweet.
(Reporting by Manas Mishra in Bengaluru; Editing by Aditya Soni)
